Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CARLSBAD, Calif., Aug. 15, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and... | August 15, 2022
Pardes Biosciences Stephen Jasper Patrick Obrien Pardes Bioscience Thomasg Wiggans Exchange Commission
Source: marketscreener.com